Teriflunomide

Teriflunomide

SCHEMBL993119

CC(O)=C(C#N)C(=O)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DHODH

The experimentally established mechanism targets of Teriflunomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
DHODH known ✓ Q02127 9/20 1.00
EPHX2 P34913 1/20 0.51
TRPV1 Q8NER1 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
ALDH1A1 P00352 2/20 0.48
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Teriflunomide SCHEMBL2760666 1.00 DHODH (1.00) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL20214092 1.00 DHODH (1.00) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL22661 1.00 DHODH (1.00) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL8466730 0.99 DHODH (0.97) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL991312 0.99 DHODH (0.97) DHODHEPHX2TRPV1NPC1RAB9A
Teriflunomide SCHEMBL992140 0.99 DHODH (0.97) DHODHEPHX2TRPV1NPC1RAB9A
SCHEMBL9079302 0.92 DHODH (0.85) DHODHEPHX2TRPV1
SCHEMBL8808801 0.92 DHODH (0.85) DHODHEPHX2TRPV1
SCHEMBL12312432 0.90 DHODH (0.82) DHODHALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL8404982 0.88 DHODH (0.79) DHODHEPHX2TRPV1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114288294-A Compounds and methods for treating or preventing hematologic cancers 布罗德研究所股份有限公司 2022-04-08 CN claimed
US-20210290585-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY UNIV RAMOT (IL) 2021-09-23 US claimed
US-11033524-B2 Methods and compositions for treating disorders associated with cortico-hippocampal hyperactivity RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2021-06-15 US claimed
EP-3310755-B1 A NOVEL PROCESS FOR THE PREPARATION OF TERIFLUNOMIDE BIOCON LTD (IN) 2021-02-24 EP claimed
EP-3344243-B1 COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS BROAD INST INC (US) 2020-12-09 EP claimed
US-20190269644-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH CORTICO-HIPPOCAMPAL HYPERACTIVITY RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2019-09-05 US claimed
US-20180263970-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS THE BROAD INSTITUTE, INC. (US) 2018-09-20 US claimed
EP-3344243-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS The Broad Institute Inc. (US) 2018-07-11 EP claimed
US-20180170859-A1 A NOVEL PROCESS FOR THE PREPARATION OF TERIFLUNOMIDE BIOCON LIMITED (IN) 2018-06-21 US claimed
EP-3310755-A1 A NOVEL PROCESS FOR THE PREPARATION OF TERIFLUNOMIDE Biocon Limited (IN) 2018-04-25 EP claimed
EP-0787491-A1 PREVENTIVE AND REMEDY FOR TYPE I ALLERGIC DISEASES HOECHST JAPAN LIMITED (JP) 1997-08-06 EP claimed
US-5624946-A Use of leflunomide to control and reverse chronic allograft rejection WILLIAMS, JAMES W. 1997-04-29 US claimed
EP-0527736-B1 ISOXAZOLE-4-CARBOXAMIDES AND HYDROXYALKYLIDENE-CYANOACETAMIDES, DRUGS CONTAINING THESE COMPOUNDS AND USE OF SUCH DRUGS HOECHST AG (DE) 1997-04-16 EP claimed
US-5532259-A ANTITUMOR HOECHST AKTIENGESELLSCHAFT (DE) 1996-07-02 US claimed
US-5519042-A Method of treating hyperproliferative vascular disease HOECHST AKTIENGESELLSCHAFT (DE) 1996-05-21 US claimed
US-5504084-A N-(4-TRIFLUOROMETHYLPHENYL) SUBSTITUTION ON 5-METHYL-ISOXAZOLE-4-CARBOXAMIDE OR 2-CYANO-3-HYDROXYCROTONAMIDE HOECHST AKTIENGESELLSCHAFT (DE) 1996-04-02 US claimed
US-5494911-A TREATING LEUKEMIA, SARCOMA, CARCINOMA, LYMPHOMA, SKIN CANCER HOECHST AKTIENGESELLSCHAFT (DE) 1996-02-27 US claimed
US-5459163-A Treatment of lupus, graft-versus-host diseases HOECHST AKTIENGESELLSCHAFT (DE) 1995-10-17 US claimed
EP-0665013-A1 Method of treating hyperproliferative vascular disease HOECHST AKTIENGESELLSCHAFT (DE) 1995-08-02 EP claimed
EP-0617959-A1 Pharmaceutical for the treatment of skin disorders HOECHST AKTIENGESELLSCHAFT (DE) 1994-10-05 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170859-A1 A NOVEL PROCESS FOR THE PREPARATION OF TERIFLUNOMIDE TMT1A, FAR1, CYP51A1 DHODH 15/4885EPHX2 1257/4885TRPV1 4005/4885
US-20180263970-A1 COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS DHODH, MCL1, DHX15 DHODH 1/4885EPHX2 57/4885TRPV1 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.